This company listing is no longer active
HQ8F Stock Overview
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Apollo Endosurgery, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.10 |
| 52 Week High | US$9.64 |
| 52 Week Low | US$3.39 |
| Beta | 2.32 |
| 1 Month Change | -0.85% |
| 3 Month Change | -1.88% |
| 1 Year Change | 70.35% |
| 3 Year Change | 386.63% |
| 5 Year Change | 92.80% |
| Change since IPO | -49.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQ8F | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.0% | -5.0% | -2.0% |
| 1Y | 70.3% | -13.6% | -0.3% |
Return vs Industry: HQ8F exceeded the German Medical Equipment industry which returned -7% over the past year.
Return vs Market: HQ8F exceeded the German Market which returned -8.6% over the past year.
Price Volatility
| HQ8F volatility | |
|---|---|
| HQ8F Average Weekly Movement | 1.4% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HQ8F has not had significant price volatility in the past 3 months.
Volatility Over Time: HQ8F's weekly volatility has decreased from 12% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 202 | Chas McKhann | www.apolloendo.com |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying, which assists the patient in losing weight under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.
Apollo Endosurgery, Inc. Fundamentals Summary
| HQ8F fundamental statistics | |
|---|---|
| Market cap | €531.72m |
| Earnings (TTM) | -€36.54m |
| Revenue (TTM) | €70.49m |
7.5x
P/S Ratio-14.6x
P/E RatioIs HQ8F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQ8F income statement (TTM) | |
|---|---|
| Revenue | US$76.86m |
| Cost of Revenue | US$34.43m |
| Gross Profit | US$42.43m |
| Other Expenses | US$82.27m |
| Earnings | -US$39.84m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 55.20% |
| Net Profit Margin | -51.84% |
| Debt/Equity Ratio | 164.7% |
How did HQ8F perform over the long term?
See historical performance and comparison